Heart-rate variability effects of β-adrenoceptor agonists (xamoterol, prenalterol, and salbutamol) assessed nonlinearly with scatterplots and sequence methods

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 6, 1999, Pages 859-867

  Silke, B ^a   Hanratty, C G ^a   Riddell, J G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Heart rate variability Scatterplot; Nonlinear; Partial agonist; Adrenoceptor

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CELIPROLOL; PLACEBO; PRENALTEROL; SALBUTAMOL; XAMOTEROL;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART INFARCTION; HEART PROTECTION; HEART RATE VARIABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NONLINEAR SYSTEM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; SLEEP;

EID: 0033017150     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199906000-00005     Document Type: Article

References (56)

1. Kleiger RE, Miller JP, Bigger JT, Moss AJ. The Multicenter Post-Infarction Research Group: decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-62.
2. Malik M, Farrell T, Cripps T, Camm AJ. Heart rate variability in relation to prognosis after myocardial infarction: selection of optimal processing techniques. Eur Heart J 1989;10:1060-74.
3. Bigger JT, Fleiss JL, Steinman R, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85: 164-71.
4. Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Engl J Med 1976;294:1165-70.
5. Spiers JP, Silke B, McDermott U, Shanks RG, Harron DWG. Time and frequency domain assessment of heart rate variability: a theoretical and clinical appreciation. Clin Autonom Res 1993;3:145-58.
6. Algra A, Tijssen JGP, Roelandt JRTC, Pool J, Lubsen J. Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 1993;88:180-5.
7. vanBoven AJ, Crijns JGM, Haaksma J, Zwinderman AH, Lie KI, Wouter-Jukema J. Depressed heart rate variability is associated with events in patients with stable coronary artery disease and preserved left ventricular function. Am Heart J 1998;135:571-6.
8. Norwegian Multicentre Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
9. Beta-Blocker Heart Attack Research Group. A randomised trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247:1707-14.
10. Molgaard H, Mickley H, Pless P, Bjerregaard P, Moller M. Effects of metoprolol on heart rate variability in survivors of acute myocardial infarction. Am J Cardiol 1993;71:1357-9.
11. Sandrone G, Mortara A, Torzillo D, La Rovere MT, Malliani A, Lombardi F. Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction. Am J Cardiol 1994;74:340-5.
12. Wheeldon NM, McDevitt DG, Lipworth BJ. Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects. Br J Clin Pharmacol 1992;34:337-43.
13. Silke B, Riddell JG. Effects of beta-adrenoceptor agonists and antagonists on heart-rate variability assessed using summary statistics and nonlinear procedures. J Cardiovasc Pharmacol 1997; 30:817-23.
14. Jartti T, Kaila T, Tahvanainen K, Kuusela T, Vanto T, Valimaki I. The acute effects of inhaled salbutamol on the beat-to-beat variability of heart rate and blood pressure assessed by spectral analysis. Br J Clin Pharmacol 1997;43:421-8.
15. Camm J, Malik M. Heart rate variability: standards of measurement, physiological interpretation, and clinical use: report of Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996; 17:354-81.
16. Raetz SL, Richard CA, Garfinkel A, Harper RM. Dynamic characteristics of cardiac R-R intervals during sleep and waking states. Sleep 1991;14:526-33.
17. Schechtman VL, Raetz SL, Harper RK, Garfinkel A, Wilson AJ, Southall DP. Dynamic analysis of cardiac R-R intervals in normal infants and in infants who subsequently succumbed to the sudden infant death syndrome. Paediatr Res 1992;31:606-12.
18. Hagerman I, Berglund M, Lorin M, Nowak J, Sylven C. Chaos-related deterministic regulation of heart rate variability in time- and frequency domains: effects of autonomie blockade and exercise. Cardiovasc Res 1996;31:410-8.
19. Hnatkova K, Copie X, Staunton A, Malik M. Numeric processing of Lorenz plots of R-R intervals from long-term ECGs: comparison with time-domain measures of heart rate variability for risk stratification after myocardial infarction. J Electrocardiogr 1995;28: 74-80.
20. Copie X, Leheuzey JY, Iliow MC, et al. Correlation between time-domain measures of heart rate variability and scatterplots in post-infarction patients. PACE Pacing Clin Electrophysiol 1996;19: 342-7.
21. Kamen PW, Krum H, Tonkin AM. Poincaré plot of heart rate variability allows quantitative display of parasympathetic nervous activity in humans. Clin Sci 1996;91:201-8.
22. McCaffrey PM, Riddell JG, Shanks RG. The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,511. J Cardiovasc Pharmacol 1988;11:543-51.
23. McCaffrey PM, Riddell JG, Shanks RG. An assessment of the partial agonist activity of Ro 31,1118, flusoxolol and pindolol in man. Br J Clin Pharmacol 1987;24:571-80.
24. Wagner J, Reinhardt D, Schumann HJ. Comparison of the bronchodilator and cardiovascular actions of isoprenaline, Th 1165a, terbutaline and salbutamol in cats and isolated organ preparations. Res Exp Med 1973;162:49-62.
25. O'Donnell SR. An examination of some beta-adrenoceptor stimulants for selectivity using the isolated trachea and atria of the guinea pig. Eur J Pharmacol 1972;19:371-9.
26. Hadfield SE, Slee S-J, Snow HM. The cardiovascular pharmacology of xamoterol, cicloprolol, prenalterol and pindolol in the anaesthetised dog. Br J Clin Pharmacol 1989;28:78S-81S.
27. Cook N, Richardson A, Barnett DB. Comparison of the beta-1 selective affinity of prenalterol and Corwin demonstrated by radioligand binding. Eur J Pharmacol 1984;98:407-12.
28. Barlow JJ, Main BG, Snow HM. Beta-adrenoceptor stimulant properties of amido alkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols. J Med Chem 1981;1981:24.
29. Nutall A, Snow HM. The cardiovascular effects of ICI 118,587: a beta-1 adrenoceptor agonist. Br J Clin Pharmacol 1982;77:381-8.
30. Jennings G, Bobik A, Oddie C, Restall R. Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol. Clin Pharmacol Ther 1984;35:594-603.
31. Kowalski MT, Haworth D, Lu X, Thomson DS, Barnett DB. Comparison of the effects of xamoterol and isoprenaline on rat cardiac beta-adrenoceptors: studies of function and regulation. Br J Pharmacol 1990;99:27-30.
32. Malik M, Cripps T, Farrell T, Camm AJ. Prognostic value of heart rate variability after myocardial infarction: a comparison of different data processing methods. Med Biol Eng Comput 1989;27:603-11.
33. SPSS I. SPSS for Windows users guide. Chicago: Norusis/SPSS, Inc., 1993.
34. Pousset F, Copie X, LeChat P, et al. Effects of bisoprolol on heart-rate variability in heart-failure. Am J Cardiol 1996;77:612-7.
35. Altman DG. Two way analysis of variance. In: Practical statistics for medical research. London: Chapman & Hall, 1992:334-6.
36. Bristow MR, Hershberger RE, Port JD, et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990;82:I-12,I-25.
37. McGibney D, Singleton W, Silke B, Taylor SH. Observations on the mechanism underlying the differences in exercise and isoprenaline tachycardia after cardioselective and non-selective beta adrenoceptor antagonists. Br J Clin Pharmacol 1983;15:15-9.
38. Silke B, Riddell JG. Heart rate variability effects of agonist or antagonists of the beta-adrenoceptor assessed with scatterplot and sequence analysis. Clin Autonom Res 1998;8:145-53.
39. Grove A, McFarlane LC, Lipworth BJ. Expression of the beta-2 partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone. Thorax 1995;50:134-8.
40. Waite R. Activite sympathomimetique intrinseque des beta-bloquants. Nouv Presse Med 1978;7:2707-9.
41. Clark BJ, Menninger K, Bertholet A. Pindolol: the pharmacology of a partial agonist. Br J Clin Pharmacol 1982;13:149S-58S.
42. Stein PK, Rottman JN, Bosner MS, Conger BM, Kleiger RE. Effects of pindolol and labetalol on heart rate variability in normal subjects. Ambul Monit 1995;8:171-8.
43. Silke B, Riddell JG. Evaluation of the effect on heart rate variability of some agents acting at the beta-adrenoceptor, using nonlinear scatterplot and sequence methods. Cardiovasc Drugs Ther 1998;12:439-48.
44. Cook JR, Bigger JT, Kleiger RE, Fleiss JL, Steinman RC, Rolnitzky LM. Effect of atenolol and diltiazem on heart rate variability in normal persons. J Am Coll Cardiol 1991;17:480-4.
45. Schweizer MW, Brachmann J, Kirchner U, et al. Heart rate variability in time and frequency domains: effects of gallopamil, nifedipine, and metoprolol compared with placebo. Br Heart J 1993; 70:252-8.
46. Hughson RL, Yamamoto Y, McCullough RE, Sutton JR, Reeves JT. Sympathetic and parasympathetic indicators of heart rate control at altitude studied by spectral analysis. J Appl Physiol 1994; 77:2537-42.
47. Niemela MJ, Airaksinen KE, Huikuri HV. Effect of beta-blockade on heart rate variability in patients with coronary artery disease. J Am Coll Cardiol 1994;23:1370-7.
48. Hohnloser SH, Klingenheben T, Zabel M, Just H. Effect of sotalol on heart rate variability assessed by Holter monitoring in patients with ventricular arrhythmias. Am J Cardiol 1993;72:67A-71A.
49. Brouwer J, Viersma JW, Vanveldhuisen DJ, et al. Usefulness of heart-rate variability in predicting drug efficacy (metoprolol vs diltiazem) in patients with stable angina. Am J Cardiol 1995;76: 759-63.
50. Keeley EC, Lange RA, Hillis LD, Joglar JA, Page RL. correlation between time-domain measures of heart rate variability and scatterplots in patients with healed myocardial infarcts and the influence of metoprolol. Am J Cardiol 1997;79:412-4.
51. Brouwer J, van Veldhuisen DJ, Man in't Veld AJ, et al. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure: the Dutch Ibopamine Multicentre Trial Study Group. J Am Coll Cardiol 1996;28: 1183-9(N).
52. Ungi I, Thury A, Csanady M. Investigation of the correlation between heart rate and heart rate variability. Comput Cardiol 1995: 189-91.
53. Ewing DJ, Neilson JMM, Travis P. New method for assessing cardiac parasympathetic activity using 24 hour electrocardiograms. Br Heart J 1984;52:396-402.
54. Coumel P, Maison-Blanche P, Catuli D. Heart rate and heart rate variability. In: Malik M, Camm AJ, eds. Heart rate variability. Armonk, NY: Futura Publishing, 1995:207-21.
55. Swynghedauw B, Jasson S, Chevalier B, et al. Heart rate and heart rate variability. Cardiovasc Drugs Ther 1996;10:677-85.
56. Zuanetti G, Latini R, Neilson JMM, Schwartz PJ, Ewing DJ. The antiarrhythmic drug evaluation group: heart rate variability in patients with ventricular arrhythmias: effect of antiarrhythmic drugs. J Am Coll Cardiol 1991;17:604-12.